风湿性与肌肉骨骼疾病患者接种SARS-CoV-2疫苗的安全性:EULAR冠状病毒疫苗(COVAX)医生报告登记研究结果
该研究基于EULAR冠状病毒疫苗(COVAX)医生报告登记研究,纳入30个国家5121例接种SARS-CoV-2疫苗的风湿性与肌肉骨骼疾病患者,其中90%为炎症性/自身免疫性风湿与肌肉骨骼疾病(I-RMD)。在完成全程接种者中,I-RMD患者突破性感染为0.7%、非炎症性风湿与肌肉骨骼疾病(NI-RMD)患者为1.1%;I-RMD疾病复发为4.4%(重度0.6%),不良事件为37%。作者认为I-RMD患者接种SARS-CoV-2疫苗的安全性令人安心,与NI-RMD患者相当。
要点
- I-RMD患者全程接种后突破性感染为0.7%,NI-RMD患者为1.1%。
- I-RMD患者疾病复发为4.4%(重度0.6%),1.5%因此调整用药。
- 不良事件为37%(I-RMD 37%、NI-RMD 40%),严重不良事件为0.5%。
核心结论
- 作者认为I-RMD患者接种SARS-CoV-2疫苗的安全性令人安心,与NI-RMD患者相当。
- 多数患者耐受良好,I-RMD复发报告少见,严重不良事件报告极少。
- 作者认为这些结果可为风湿科医生和受种者提供安心,并增强对I-RMD患者接种SARS-CoV-2疫苗安全性的信心。
研究设计与样本
- 医生报告登记研究,纳入已接种SARS-CoV-2疫苗的I-RMD与NI-RMD患者。
- 2021年2月5日至2021年7月27日收集人口学、疫苗接种、RMD诊断、疾病活动度、免疫调节/免疫抑制治疗、复发、不良事件(AE)和SARS-CoV-2突破性感染数据。
- 共纳入30个国家5121例参与者,90%为I-RMD(n=4604,女性68%,平均年龄60.5岁),10%为NI-RMD(n=517,女性77%,平均年龄71.4岁)。
- 数据采用描述性分析。
主要发现
- 最常见的诊断类别为炎症性关节病(58%)、结缔组织病(18%)和血管炎(12%)。
- 54%接受传统合成改善病情抗风湿药(DMARDs),42%接受生物制剂DMARDs,35%接受免疫抑制剂。
- 多数患者接种辉瑞/BioNTech疫苗(70%),17%接种阿斯利康/牛津疫苗,8%接种Moderna疫苗。
- 全程接种者中,突破性感染在I-RMD患者为0.7%、NI-RMD患者为1.1%。
- I-RMD复发为4.4%(重度0.6%),1.5%导致用药改变;不良事件为37%(I-RMD 37%、NI-RMD 40%),严重不良事件为0.5%(I-RMD 0.4%、NI-RMD 1.9%)。
关键数值与推荐
- I-RMD患者全程接种后突破性感染为0.7%,NI-RMD患者为1.1%。
- I-RMD复发为4.4%,其中重度0.6%,1.5%导致用药改变。
- 不良事件为37%(I-RMD 37%、NI-RMD 40%),严重不良事件为0.5%(I-RMD 0.4%、NI-RMD 1.9%)。
- 疫苗接种构成:辉瑞/BioNTech 70%、阿斯利康/牛津17%、Moderna 8%。
临床怎么用
- 作者认为这些结果可为风湿科医生和受种者提供安心,并增强对I-RMD患者接种SARS-CoV-2疫苗安全性的信心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). METHODS: Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, RMD diagnosis, disease activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) and SARS-CoV-2 breakthrough infections. Data were analysed descriptively. RESULTS: The study included 5121 participants from 30 countries, 90% with I-RMDs (n=4604, 68% female, mean age 60.5 years) and 10% with NI-RMDs (n=517, 77% female, mean age 71.4). Inflammatory joint diseases (58%), connective tissue diseases (18%) and vasculitis (12%) were the most frequent diagnostic groups; 54% received conventional synthetic disease-modifying antirheumatic drugs (DMARDs), 42% biological DMARDs and 35% immunosuppressants. Most patients received the Pfizer/BioNTech vaccine (70%), 17% AstraZeneca/Oxford and 8% Moderna. In fully vaccinated cases, breakthrough infections were reported in 0.7% of I-RMD patients and 1.1% of NI-RMD patients. I-RMD flares were reported in 4.4% of cases (0.6% severe), 1.5% resulting in medication changes. AEs were reported in 37% of cases (37% I-RMD, 40% NI-RMD), serious AEs in 0.5% (0.4% I-RMD, 1.9% NI-RMD). CONCLUSION: The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.
引用
- Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021. PMID: 34972811. doi:10.1136/annrheumdis-2021-221490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。